| Drug General Information |
| Drug ID |
D0L6RF
|
| Former ID |
DIB010484
|
| Drug Name |
BAY1179470
|
| Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 1 |
[1]
|
|---|
| Company |
Bayer healthcare pharmaceuticals
|
| Target and Pathway |
| Target(s) |
Fibroblast growth factor receptor 2 |
Target Info |
Antagonist |
[2]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Regulation of actin cytoskeleton
|
|
Pathways in cancer
|
|
Prostate cancer
|
|
Central carbon metabolism in cancer
|
|
NetPath Pathway
|
IL1 Signaling Pathway
|
|
PANTHER Pathway
|
FGF signaling pathway
|
|
Pathway Interaction Database
|
FGF signaling pathway
|
|
Reactome
|
Activated point mutants of FGFR2
|
|
WikiPathways
|
Regulation of Actin Cytoskeleton
|
|
Ectoderm Differentiation
|
|
Hair Follicle Development: Organogenesis (Part 2 of 3)
|
|
Hair Follicle Development: Induction (Part 1 of 3)
|
|
Cardiac Hypertrophic Response
|
|
Signaling Pathways in Glioblastoma
|
|
Neural Crest Differentiation
|
|
Signaling by FGFR
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Angiogenesis
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01881217) First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors. U.S. National Institutes of Health. |
|---|
| REF 2 | National Cancer Institute Drug Dictionary (drug id 751593). |
|---|
